Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCD versus CVD for first relapse or primary refractory multiple myeloma
ISRCTN17354232Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised trial of carfilzomib, cyclophosphamide, dexamethasone and bortezomib in multiple myeloma (MM) (2 arms), sponsored by University of Leeds. Primary endpoint: Proportion of participants achieving at least very good partial response. Started Jan 2013; status: completed.
02
Drugs
carfilzomibcyclophosphamidedexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN17354232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17354232.